Pathophysiology and treatment of diabetic retinopathy (Q34528134)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article

Language	Label	Description	Also known as
English	Pathophysiology and treatment of diabetic retinopathy	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

1 reference

Europe PubMed Central

Pathophysiology and treatment of diabetic retinopathy (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

pathophysiology

1 reference

based on heuristic

inferred from title

Francesco Bandello

1

object named as

Francesco Bandello

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

author name string

Rosangela Lattanzio

2

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Ilaria Zucchiatti

3

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Claudia Del Turco

4

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

publication date

1 January 2013

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Acta Diabetologica

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

50

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

1-20

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005-2050.

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Diabetic macular edema: pathogenesis and treatment

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Clinical review: The role of advanced glycation end products in progression and complications of diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Retinal heat shock protein 25 in early experimental diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

AGEs, RAGE, and diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Aldose reductase in diabetic microvascular complications

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

The polyol pathway as a mechanism for diabetic retinopathy: attractive, elusive, and resilient

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Activation of protein kinase C isoforms and its impact on diabetic complications

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Homocysteine levels in the vitreous of proliferative diabetic retinopathy and rhegmatogenous retinal detachment: its modulating role on lysyl oxidase

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Oxidative stress and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Immunological mechanisms in the pathogenesis of diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Expression of lysophosphatidic acid, autotaxin and acylglycerol kinase as biomarkers in diabetic retinopathy.

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Vascular endothelial growth factor-A: a multifunctional molecular player in diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Angiotensin-(1-7) suppresses oxidative stress and improves glucose uptake via Mas receptor in adipocytes

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Diabetic Retinopathy

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Local multifocal oscillatory potential abnormalities in diabetes and early diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Multifocal electroretinogram and short-wavelength automated perimetry measures in diabetic eyes with little or no retinopathy

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Glutamate-induced apoptosis in neuronal cells is mediated via caspase-dependent and independent mechanisms involving calpain and caspase-3 proteases as well as apoptosis inducing factor (AIF) and this process is inhibited by equine estrogens

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

The potential role of glutamate in the current diabetes epidemic.

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Diabetes downregulates presynaptic proteins and reduces basal synapsin I phosphorylation in rat retina

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Involvement of brain-derived neurotrophic factor in early retinal neuropathy of streptozotocin-induced diabetes in rats: therapeutic potential of brain-derived neurotrophic factor for dopaminergic amacrine cells

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Müller cell-derived VEGF is essential for diabetes-induced retinal inflammation and vascular leakage

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Occludin phosphorylation and ubiquitination regulate tight junction trafficking and vascular endothelial growth factor-induced permeability

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Endothelium-specific platelet-derived growth factor-B ablation mimics diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Effect of obesity and glycemic control on serum lipocalins and insulin-like growth factor axis in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Management of newly diagnosed patients with type 2 diabetes: what are the attitudes of physicians? A SUBITO!AMD survey on the early diabetes treatment in Italy.

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Post-prandial glucose and diabetic complications: systematic review of observational studies

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study.

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Effect of trandolapril on regression of retinopathy in hypertensive patients with type 2 diabetes: a prespecified analysis of the benedict trial

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Insulin resistance is associated with elevated serum pigment epithelium-derived factor (PEDF) levels in morbidly obese patients

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Lipid accumulation in overweight type 2 diabetic subjects: relationships with insulin sensitivity and adipokines

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Selective activation of peroxisome proliferator-activated receptor (PPAR)alpha and PPAR gamma induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism.

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Diabetic macular edema. A review

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Prevalence of diabetic retinopathy in the United States, 2005-2008.

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

The 25-year incidence of visual impairment in type 1 diabetes mellitus the wisconsin epidemiologic study of diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Blindness in a 25-year follow-up of a population-based cohort of Danish type 1 diabetic patients

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Burden of illness of diabetic macular edema: literature review

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Steroids as part of combination treatment: the future for the management of macular edema?

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Progressive Enlargement of Laser Scars Following Grid Laser Photocoagulation for Diffuse Diabetic Macular Edema

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Short-duration focal pattern grid macular photocoagulation for diabetic macular edema: four-month outcomes

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

"Light" versus "classic" laser treatment for clinically significant diabetic macular oedema

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Micropulse and continuous wave diode retinal photocoagulation: visible and subvisible lesion parameters

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Microperimetry and fundus autofluorescence in diabetic macular edema: subthreshold micropulse diode laser versus modified early treatment diabetic retinopathy study laser photocoagulation

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Functional outcome of subthreshold versus threshold diode laser photocoagulation in diabetic macular oedema

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema.

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Randomized clinical trial evaluating mETDRS versus normal or high-density micropulse photocoagulation for diabetic macular edema

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Selective retinal therapy with microsecond exposures using a continuous line scanning laser

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Semiautomated patterned scanning laser for retinal photocoagulation

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Healing of retinal photocoagulation lesions

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Pain responses of Pascal 20 ms multi-spot and 100 ms single-spot panretinal photocoagulation: Manchester Pascal Study, MAPASS report 2.

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Comparison of laser photocoagulation for diabetic retinopathy using 532-nm standard laser versus multispot pattern scan laser

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Experience with the Pascal® photocoagulator: an analysis of over 1,200 laser procedures with regard to parameter refinement

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Spectral-domain optical coherence tomography imaging of retinal changes after conventional multicolor laser, subthreshold micropulse diode laser, or pattern scanning laser therapy in Japanese with macular edema

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Clinical evaluation and treatment accuracy in diabetic macular edema using navigated laser photocoagulator NAVILAS.

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Pain and accuracy of focal laser treatment for diabetic macular edema using a retinal navigated laser (Navilas).

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Time required for navigated macular laser photocoagulation treatment with the Navilas

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Effect of pulse duration on size and character of the lesion in retinal photocoagulation

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Initial experience with the Pascal photocoagulator: a pilot study of 75 procedures

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Fundus autofluorescence and Fourier-domain optical coherence tomography imaging of 10 and 20 millisecond Pascal retinal photocoagulation treatment.

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Recent advances in drug delivery systems for treating ocular complications of systemic diseases

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema.

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema.

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Intravitreal steroids for macular edema: the past, the present, and the future

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Role of steroids in the treatment of diabetic macular edema

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Role of steroids in the management of diabetic macular edema and proliferative diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Intravitreal triamcinolone prior to laser treatment of diabetic macular edema: 24-month results of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Intravitreal triamcinolone as an adjunct to standard laser therapy in coexisting high-risk proliferative diabetic retinopathy and clinically significant macular edema

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Association of vitreous inflammatory factors with diabetic macular edema

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months.

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2.

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3.

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study).

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study).

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Concentration of vascular endothelial growth factor after intracameral bevacizumab injection in eyes with neovascular glaucoma

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Intravitreal bevacizumab and aqueous shunting surgery for neovascular glaucoma: safety and efficacy

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Pegaptanib for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Changes in vision- and health-related quality of life in patients with diabetic macular edema treated with pegaptanib sodium or sham

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Use of pegaptanib for recurrent and non-clearing vitreous haemorrhage in proliferative diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema.

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Subconjunctival sirolimus in the treatment of diabetic macular edema

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Ocular oxygenation and the treatment of diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Intraocular VEGF level as a risk factor for postoperative complications after vitrectomy for proliferative diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Vitrectomy for diabetic macular edema: the role of posterior vitreous detachment and epimacular membrane

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Optical cross-sectional observation of resolved diabetic macular edema associated with vitreomacular separation

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Surgery for diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Vitrectomy for diabetic macular oedema

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Long-term follow-up of vitrectomy for diffuse nontractional diabetic macular edema

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Inhibitors of ocular neovascularization: promises and potential problems.

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Combined rhegmatogenous and traction retinal detachment in proliferative diabetic retinopathy: clinical manifestations and surgical outcome

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Corneal epithelial defects following vitrectomy surgery using hand-held, sew-on, and noncontact viewing lenses

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Predictive clinical features and outcomes of vitrectomy for proliferative diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Surgical management of the late complications of proliferative diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Surgical and visual outcome following 20-gauge vitrectomy in proliferative diabetic retinopathy over a 10-year period, evidence for change in practice

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Intravitreal triamcinolone reduces the morphologic changes of ciliary body after pars plana vitrectomy for retinal vascular diseases

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Combination of vitrectomy, IVTA, and laser photocoagulation for diabetic macular edema unresponsive to prior treatments; 3-year results

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

One-year results of a multicenter controlled clinical trial of triamcinolone in pars plana vitrectomy

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR).

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Fibrovascular ingrowth and recurrent haemorrhage following diabetic vitrectomy

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Enzymatic vitreolysis.

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Pooled efficacy results from two multinational randomized controlled clinical trials of a single intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage.

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

A placebo-controlled trial of microplasmin intravitreous injection to facilitate posterior vitreous detachment before vitrectomy

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

INTRAVITREAL BEVACIZUMAB AND PANRETINAL PHOTOCOAGULATION FOR PROLIFERATIVE DIABETIC RETINOPATHY ASSOCIATED WITH VITREOUS HEMORRHAGE

1 reference

https://api.crossref.org/works/10.1007%2FS00592-012-0449-3

21 January 2018

Identifiers

10.1007/S00592-012-0449-3

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34528134&oldid=2196740947"